Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: inhibitor, mCRPC, niraparib, olaparib, PARP, Phase III, rucaparib, talazoparib | 5 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 